Tevogen Stock Surges on Expanded Microsoft AI Collaboration

Seeking Alpha
01-25

Tevogen Bio (NASDAQ:TVGN) stock jumped nearly 26% post-market after the company announced it has expanded its relationship with Microsoft (NASDAQ:MSFT) to broaden their AI-focused collaboration and build its PredicTcell technology for predictive precision T cell targeting.

The Tevogen.AI initiative will integrate Microsoft's AI tools and Azure cloud platform to expand Tevogen's (NASDAQ:TVGN) ExacTcell preclinical pipeline. The initiative will also aim to develop proprietary algorithms to decode HLA-T cell interactions, according to a statement.

The company added it is also investigating potential treatments for HPV and identifying cytotoxic T cell targets to select for a clinical trial for its first oncology drug candidate, TVGN 920.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10